AbbVie and Boehringer Ingelheim to develop and commercialize BI 655066

[Fred]

More good news for BI 655066 after AbbVie and Boehringer Ingelheim today announced a global development and commercialization collaboration. BI 655066 has achieved psoriasis clearance for 66 months from one shot in a previous study.

Quote:

---

AbbVie (NYSE: ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evaluating the potential of this biologic therapy in Crohn's disease, psoriatic arthritis and asthma. In addition to the anti-IL-23 antibody, AbbVie gains rights to an anti-CD-40 antibody, BI 655064, currently in Phase 1 development. Boehringer Ingelheim will retain responsibility for further development of BI 655064, and AbbVie may elect to advance the program after completion of certain undisclosed clinical achievements.

"This collaboration positions BI 655066 as AbbVie's lead investigational compound in psoriasis, complementing our robust immunology pipeline," said Michael E. Severino, M.D., executive vice president and chief scientific officer, AbbVie. "Our expertise in developing and commercializing the world's leading biologic, combined with Boehringer Ingelheim's clinical success to-date will enable us to offer patients a new treatment option with the potential to meaningfully improve the standard of care."

"Our Immunology R&D teams have successfully brought forward compounds that have the potential to transform the way immune diseases are treated. I believe the collaboration with AbbVie is the best way to ensure broad access for patients to BI 655066 and BI 655064," said Dr. Michel Pairet, Member of the Board of Managing Directors responsible for R&D nonclinical at Boehringer Ingelheim. "Our company remains strongly committed to establishing immunology as a core area of expertise and building our pipeline and capabilities in this important therapeutic area."

Recent Phase 2 head-to-head study results in patients with moderate-to-severe plaque psoriasis showed that BI 655066 had greater efficacy over ustekinumab, a commonly used treatment for this life-impacting skin condition. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab. Patients also achieved this skin clearance faster (approximately eight weeks versus approximately 16 weeks) and for more than two months longer (≥ 32 weeks versus 24 weeks) than those on ustekinumab. In addition, completely clear skin (PASI 100) was maintained after nine months in nearly triple the percentage of patients on BI 655066 compared with ustekinumab (43 percent versus 15 percent).

Source: abbvie.com

More on BI 655066

Psoriasis clear 66 months after one subcutaneous injection of trial drug BI 655066

New psoriasis treatment BI 655066 worked faster than Stelara

[jiml]

This is more good news in the development of this drug now at a phase 3 trial and doing well, I hope this comes to market soon and gives dermatologists and rheumatologist more options for treating the diseases
As well as the possibility of use for Crohn's disease and asthma

It's good to see these new drugs coming online....the futures looking brighter

[Fred]

It's good to see these new drugs coming online....the futures looking brighter  

Yep and not before time. It seems at least in the past few years that things a finally going to get better for people with psoriasis and psoriatic arthritis.

[Caroline]

Certainly for the people with Crohns this is very important. There is currently not much to give an answer to treat Crohns.

[Kit]

Certainly for the people with Crohns this is very important. There is currently not much to give an answer to treat Crohns.

I have an 18 year old granddaughter who has recently been diagnoses   diagnosed! with Crohns - She and the family of course, are pretty badly shaken.
So - it's good to see some hope on this front too.

Kit

[Caroline]

Certainly for the people with Crohns this is very important. There is currently not much to give an answer to treat Crohns.

I have an 18 year old granddaughter who has recently been diagnoses   diagnosed! with Crohns - She and the family of course, are pretty badly shaken.
So - it's good to see some hope on this front too.

Kit

I am sorry to hear that Kit, that is a very inconvenient disease, and only 18.
Btw, DMF is also anti-Crohns....

[mataribot]

What is really needed is a weight based dose (a real one). How fast these new biologics work is based on the loading dose. Overloading on the starting dose may bring quicker results, but it is at the expense of the maintenance dose

[Fred]

What is really needed is a weight based dose (a real one). How fast these new biologics work is based on the loading dose. Overloading on the starting dose may bring quicker results, but it is at the expense of the maintenance dose

That's a good point. As you know Stelara is 45mg but goes up to 90mg at 100kg, when I started playing with the dose myself and the dermatologist thought it would be good if we could try something in between the two. But I ended up on 90mg and I weigh 92kg, so one could argue that I'm getting too much or maybe that is why it's no longer working as well as it used to.

[mataribot]

There probably several reasons that are over my head. However, my guess is the maintenance dose is not enough. The further away you get from the loading dose or if you miss a dose the more problems you have.

[Fred]

There probably several reasons that are over my head. However, my guess is the maintenance dose is not enough. The further away you get from the loading dose or if you miss a dose the more problems you have.

Interesting thoughts, but like you it's all over my head too.